Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
What a wobby AI trade could mean for Anthropic's IPO
Despite recent AI jitters, strategists expect strong demand for Anthropic’s potentially historic IPO.
stocks
Investor Playbook: What Transurban, APA and Deterra have in common?
What inflation-resistant businesses have in common.
stocks
Our view after REA’s share price rally
A bullish market reaction but valuation concerns remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,163.40 | 18.70 | 0.20% |
| CAC 40 | 8,235.50 | 96.50 | 1.19% |
| DAX 40 | 26,265.56 | 445.20 | 1.72% |
| Dow JONES (US) | 52,180.21 | 894.48 | 1.74% |
| FTSE 100 | 10,779.32 | 105.38 | 0.99% |
| HKSE | 24,448.95 | 32.91 | -0.13% |
| NASDAQ | 25,113.93 | 534.50 | 2.17% |
| Nikkei 225 | 58,775.50 | 1,340.73 | 2.33% |
| NZX 50 Index | 13,973.62 | 24.88 | -0.18% |
| S&P 500 | 7,517.11 | 140.25 | 1.90% |
| S&P/ASX 200 | 9,029.70 | 8.90 | 0.10% |
| SSE Composite Index | 3,660.79 | 11.61 | 0.32% |